72 related articles for article (PubMed ID: 38612869)
1. Clinicopathological Significance of Cyclin-Dependent Kinase 2 (CDK2) in Ductal Carcinoma In Situ and Early-Stage Invasive Breast Cancers.
Lashen A; Alqahtani S; Shoqafi A; Algethami M; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732271
[TBL] [Abstract][Full Text] [Related]
2. GCN-5/PGC-1α signaling is activated and associated with metabolism in cyclin E1-driven ovarian cancer.
Guo T; Li B; Gu C; Chen X; Han M; Liu X; Xu C
Aging (Albany NY); 2019 Jul; 11(14):4890-4899. PubMed ID: 31313989
[TBL] [Abstract][Full Text] [Related]
3. Alterations of pRb1-cyclin D1-cdk4/6-p16(INK4A) pathway in endometrial carcinogenesis.
Semczuk A; Jakowicki JA
Cancer Lett; 2004 Jan; 203(1):1-12. PubMed ID: 14670612
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Strategies for RB1-Deficient Cancers: Intersecting Gene Regulation and Targeted Therapy.
Huang MF; Wang YX; Chou YT; Lee DF
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672640
[TBL] [Abstract][Full Text] [Related]
5. The Clinicopathological Significance of the Cyclin D1/E1-Cyclin-Dependent Kinase (CDK2/4/6)-Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers.
Lashen A; Algethami M; Alqahtani S; Shoqafi A; Sheha A; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612869
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells.
Sweeney KJ; Sarcevic B; Sutherland RL; Musgrove EA
Oncogene; 1997 Mar; 14(11):1329-40. PubMed ID: 9178893
[TBL] [Abstract][Full Text] [Related]
7. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
Prall OW; Sarcevic B; Musgrove EA; Watts CK; Sutherland RL
J Biol Chem; 1997 Apr; 272(16):10882-94. PubMed ID: 9099745
[TBL] [Abstract][Full Text] [Related]
8. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
[TBL] [Abstract][Full Text] [Related]
9. Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma.
Matsumoto M; Furihata M; Ishikawa T; Ohtsuki Y; Ogoshi S
Br J Cancer; 1999 Apr; 80(1-2):256-61. PubMed ID: 10390005
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin-H.
Higashi H; Suzuki-Takahashi I; Saitoh S; Segawa K; Taya Y; Okuyama A; Nishimura S; Kitagawa M
Eur J Biochem; 1996 Apr; 237(2):460-7. PubMed ID: 8647086
[TBL] [Abstract][Full Text] [Related]
11. Targeting DNA damage repair precision medicine strategies in cancer.
Brownlie J; Kulkarni S; Algethami M; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Curr Opin Pharmacol; 2023 Jun; 70():102381. PubMed ID: 37148685
[TBL] [Abstract][Full Text] [Related]
12. The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers.
Tang H; Kulkarni S; Peters C; Eddison J; Al-Ani M; Madhusudan S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108451
[TBL] [Abstract][Full Text] [Related]
13. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer.
Győrffy B
Geroscience; 2023 Jun; 45(3):1889-1898. PubMed ID: 36856946
[TBL] [Abstract][Full Text] [Related]
14. Amplified therapeutic targets in high-grade serous ovarian carcinoma - a review of the literature with quantitative appraisal.
Talbot T; Lu H; Aboagye EO
Cancer Gene Ther; 2023 Jul; 30(7):955-963. PubMed ID: 36804485
[TBL] [Abstract][Full Text] [Related]
15. Towards Personalized Management of Ovarian Cancer.
Algethami M; Kulkarni S; Sadiq MT; Tang HKC; Brownlie J; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Cancer Manag Res; 2022; 14():3469-3483. PubMed ID: 36545222
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
